Allergy Therapeutics (AGY)

 

Latest News

Issue of Equity

RNS Number: 3752C Allergy Therapeutics PLC 13 April 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Issue of equity in respect of the exercise of warrants and options 13 April 2017 Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces the issue and allotment ofa total n...

Hardman Research: Development across portfolio

RNS Number: 5821B Allergy Therapeutics PLC 05 April 2017 Hardman Research: Progressive development across portfolio Progressive development across portfolio - AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a 'Named Patient' basis. Tr...

Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLC

Numis today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 4...

Interim Results for six months ended 31 Dec 2016

RNS Number: 8178A Allergy Therapeutics PLC 29 March 2017 Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a meeting and call for analysts to provide an update on the Group, followed by a Q&A session, at 0900 BST today. Dial-in details are: +44 (0) 1452 555566. Conference ID: 75062637. Allergy Therapeutics plc ("Allergy Th...

All News

DateHeadlineSource
13-04-17Issue of EquityRNS
05-04-17Hardman Research: Development across portfolioRNS
04-04-17Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
29-03-17Interim Results for six months ended 31 Dec 2016RNS
16-03-17Allergy Therapeutics recruits first patient in birch pollen trial StockMarketWire
16-03-17First Patient in Pivotal Phase III Birch StudyRNS
09-03-17Notice of Interim ResultsRNS
14-02-17Broker Forecast - Stifel issues a broker note on Allergy Therapeutics PLCStockMarketWire
14-02-17Allergy Therapeutics vaccine gains CTA spprovalStockMarketWire
14-02-17House Dust Mite Allergy Vaccine Gains CTA ApprovalRNS
08-02-17Directorate ChangeRNS
01-02-17Allergy Therapeutics positive data in peanut allergy vaccineStockMarketWire
01-02-17Positive Efficacy & Safety Data in Peanut VaccineRNS
20-01-17Hardman Research: Investment driving market shareRNS
19-01-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
19-01-17Allergy Therapeutics revenues up StockMarketWire
19-01-17Trading UpdateRNS
09-01-17Top 10 small-cap share tips for 2017Interactive Investor
06-01-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
30-12-16Grant of AwardsRNS
25-11-16Allergy Therapeutics resolutions passed at AGMStockMarketWire
24-11-16Result of AGMRNS
02-11-16Allergy Therapeutics granted EU patent StockMarketWire
02-11-16EU Patent Office grants patent for MCTRNS
27-10-16Issue of equity in respect of exercise of optionsRNS
24-10-16Annual Report and AccountsRNS
14-10-16Share of the week: Tipped to double againInteractive Investor
10-10-16New data from novel adjuvant systemRNS
03-10-16Issue of equity in respect of exercise of optionsRNS
29-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
29-09-16Director/PDMR ShareholdingRNS
28-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
28-09-16Director/PDMR ShareholdingRNS
26-09-16Allergy Therapeutics tipped to bounce backInteractive Investor
26-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
26-09-16Director/PDMR ShareholdingRNS
26-09-16Hardman Research: Performance drives market shareRNS
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics Preliminary ResultsRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory